 Retention time (RT) and collision cross section (CCS) prediction of small-molecule drugs  Single and combined artificial neural network prediction models of RT and CCS  Prediction errors evaluated with external validation set  91.9% within both 2 minutes RT error and 5% relative CCS (combined ANN model)
Introduction
Liquid chromatography coupled to high resolution accurate mass spectrometry (LC-HRMS) has enabled comprehensive toxicological screening of large numbers of trace contaminants in complex matrices such as biological samples and environmental matrices [1] [2] [3] [4] [5] [6] . The addition of ion mobility spectrometry (IMS) has recently represented a significant increase in capability and allows for separation of ions in the gas-phase based on their mobility differences in an applied electric field [7, 8] .
Ions are then measured by their drift times through a tube containing a buffer gas. While drift times are system dependent, the average collision cross sections (CCS) between the ion and buffer gas can be derived when using constant operating procedures. The CCS of an ion is correlated to its size, shape, and charge. After calibration, the drift times observed from a travelling-wave IMS (TW-IMS) system can be used to determine CCS values [9] . CCS from TW-IMS have been shown to be matrix and system independent [10, 11] , and the use of LC-IMS-HRMS have been used to reduce the number of false-positive identifications and can replace other screening metrics for confirmatory analysis as a result (e.g. isotopic pattern match and fragment ions) [12] . The use of RT and CCS for confirmatory analyses means there also exists a lesser need for data-dependent fragmentation as the full-scan HRMS fragmentation can be filtered both on RT and drift time alignment [7] . This can then be applied to targeted, suspect, and non-targeted screening as required using the same dataset.
A common challenge, particularly in forensic screening, is keeping methods updated with relevant compounds. More than two new psychoactive substances enter the American and European drug market every week, on average [13, 14] . Also, with the increase of long-distance travel for vacations and work, local populations can be exposed to pollutants and drugs not prescribed in their home countries. Suspect and non-targeted screening approaches have been utilized for identification of
compounds before acquisition of reference standards [4, [15] [16] [17] . For this purpose, in-silico fragmentation matching [18, 19] and prediction of retention time (RT) have been shown to reduce the list of potential compounds [1, 20] . In-silico prediction of CCS and IMS drift times have utilized molecular modelling techniques [21] [22] [23] ; however, models based on molecular descriptors have shown similar results while drastically reducing computing time [24] [25] [26] [27] , which corresponds to findings for prediction of the reduced ion mobility constants [28, 29] .
The aim of this work was to predict both RT and CCS with the use of artificial neural networks (ANNs), a machine learning technique that has been demonstrated for predicting analytical reference values, and has only very recently been utilized for prediction of either RT [1, 30] or CCS [24] for use in screening. However, combination of these tools to understand their added value for preliminary suspect identifications has not yet been performed. A previously developed ANN model for RT prediction was trained and validated herein on a new, significantly larger dataset gathered under different LC conditions and in a different laboratory; ANN and linear regression models for prediction of CCS were trained and validated, and finally a combined model for prediction of both RT and CCS simultaneously was critically evaluated. This novel approach to in silico prediction of both RT and CCS alongside the use of HRMS data will markedly increase the speed and confidence in tentative identifications of potentially large numbers of new compounds.
Materials and methods

Chemicals
Reference standards of pharmaceuticals, drugs of abuse, and their metabolites were purchased from Lipomed GmbH (Bad Säckingen, Germany), Cerilliant (Round Rock, TX, USA), Toronto Research
Chemicals (Toronto, Canada), and SelleckChem (Houston, TX, USA). All reference standards were of ≥98% purity. Methanol, water, acetonitrile, propanol, and formic acid (LC-MS grade) were obtained from Fisher Scientific (Loughborough, UK). Leucine enkephalin was purchased from Sigma-Aldrich (Copenhagen, Denmark).
Instrumentation
Analyses were performed on two separate systems, an ultra-high performance liquid chromatographytime-of-flight mass spectrometer (UHPLC-TOF; System 1) and a UHPLC-TW-IMS-TOF (System 2). 
Reference values
In total, RTs for 869 compounds were determined from reference standards (Dataset I). Of these, the CCS of the proton adduct was determined for 364 compounds (Dataset II). For both datasets, compounds identified as multiple LC peaks were excluded. RTs were recorded on both systems, however, only RTs from System 1 was used for prediction. The differences in dataset sizes were primarily due to reference standards only being analyzed on System 1. Other factors were no observed protonation adducts, either due to high affinity for metal adducts or heavy in-source fragmentation.
Molecular descriptor generation
A total of 869 unique simplified molecular-input line-entry system (SMILES) strings were generated with ChemScript v16.0 from PerkinElmer (Waltham, MA, USA) from an in-house database of molfiles. Each SMILES string corresponded to a single compound and was used to generate a total of 105 molecular descriptors with Parameter Client freeware [31, 32] . The selected descriptors were 
Modelling CCS data by linear regression
Results and Discussion
Thirty-one compounds were removed due to peak splitting of the early-eluting compounds (<1.1 min), and an additional eleven compounds were removed due to failed descriptor generation, 42 in total for Dataset I and seven for Dataset II. RT and CCS values, SMILES, and molecular descriptors are available in Table A .1 for included compounds. The molecular descriptors evaluated in this work were limited to the groups: constitutional descriptors, functional group counts, and molecular properties, comprising 124 molecular descriptors. However, the presented RT prediction of Models RT1 & RT2 was based upon previous work that had sampled a larger number of molecular descriptors [1, 30, 33] .
Retention time modelling
All RT values were an average of at least four measurements obtained from mixtures of reference standards in solvents. RTs were not determined in spiked matrix samples since little to no influence of matrix on RTs (±0.02 min) have been observed with whole blood on System 1 [4] . In Table 1 , key values of the prediction errors of all three RT models are given, and Figure 1 shows measured RT versus predicted RT. Predicted RT values for each compound is available in Table A Model RT1 showed improved prediction accuracy compared to Models RT2 & RT-CCS regarding the full external validation. This difference is most likely due to a larger optimization set and the difference in compounds available for optimization. Dataset I contained a larger variety of pharmaceutical compounds than Dataset II, and these were, therefore, not available in the optimization of Models RT2 & RT-CCS. This is shown by the difference in the prediction errors between the external validation sets when Dataset I was/was not included. This difference can be illustrated with principal component analysis based on the descriptors as shown in figure 2 . The principal component analysis shows that models limited to Dataset II in the optimization have smaller applicability domain than those optimized on Dataset I. Model RT-CCS showed a small improvement over Model RT2, which can be explained by the descriptors being selected specifically for this dataset and, therefore, this analytical system. In general, this shows the need to retrain ANN prediction models when the experimental values are system dependent and the limitation that only compounds similar to the compounds of the optimization can be expected to fall within prediction error tolerances.
Collisional Cross-section modelling
The CCS of the protonated adduct was for all compounds in the range 128-250 Å 2 . All CCS values were an average of at least four measurements obtained from mixtures of reference standards in solvents. Predicted CCS values are available in Table A .4 . A summary of the performance of models for CCS prediction is presented in Table 2 . The linear regression using MW provided a good prediction; however, the ANN models improved upon this, and a less than 5% relative prediction error Other studies have predicted RT [1] and CCS [24] with ANNs, albeit separately, and found they could add confidence to identifications in suspect and non-targeted screening. However, our CCS prediction errors are slightly lower than those of Bijlsma et al. [24] , most likely due to their smaller number of CCS cases used for optimization (205 vs 321), and their larger CCS value range (132-307 Å 2 vs 128-250 Å 2 ). That said, it was via the combination of both tools that the most significant advancement in in
silico capability was observed. Overall, the simultaneous RT-CCS model developed here achieved prediction accuracy within 2 minutes for 88.6% (n=733) of predicted RT values, and 95.2% (n=340) of predicted CCS values were within 5% relative error. Impressively, the true-positive rate was 91.9% (n=328) and 99.4% (n=355), when the criteria for both or either of predicted values were within their error limits, respectively. These limits retain a reasonable number of the true-positive identifications and represent a significant improvement in in silico predictive capability for screening which has not been demonstrated previously to our knowledge. However, the correlation between MW and CCS indicates a lack of accuracy amongst isomers and isobars, which is relevant since the predictions are intended as orthogonal identification criterions to accurate mass measurements. The predicted CCS were not orthogonal to accurate mass measurements in this study, as illustrated by the isomers, dosulepin and pizotifen. These isomers had a 4.7% relative CCS difference, which was the largest difference of CCS values between isomers in Dataset II. Tentative identification based on the predicted CCS values was possible when ranking was based on the prediction error; however, in both cases, they were within a 3% relative CCS error limit. When grouping Dataset II by exact mass with a tolerance of 3 mDa, 26 groups contain 2-4 compounds, in total, 60 compounds. The true-positive rate for these compounds were 96.7% (n=58) when applying both filters. However, the false-positive rate was 84.1% (n=74), and in 23.3% (n=14) of identifications a potential false-positive identification was removed. In two of these 14 cases, the false-positive identification was avoided based on predicted CCS. While this number shows room for improvement, it should be remembered these numbers are mostly based on filtering of structurally related isomers. When these limits are applied to large suspect and non-targeted databases, the true-positive rate will stay the same; while the false-positive rate will likely decrease.
Similarly, when suspect and non-targeted screening are applied to authentic samples, the predicted 
Conclusion
Prediction models for RT, CCS, and a combination thereof have been presented. ANN prediction can support tentative identifications in suspect and non-target screening; however, limited selectivity between isomers and isobars were observed. The presented models include a large range of smallmolecule compounds of toxicological interest, and prediction accuracies were reliant on the number and diversity of compounds used in optimization and testing. Overall, the use of simple molecular descriptors, which can be generated for new compounds in a matter of minutes, allowed for fast prediction of RT and CCS, enabling application in large compound databases like those used in suspect and non-targeted screening.
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